Skip to main content

Table 2 Distribution of clinicopathological parameters in 1,000 high-risk breast cancer patients

From: Carbonic anhydrase IX and response to postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of the DBCG82 b and c trials

   Radiotherapy No radiotherapy χ2
All   489 (49%) 511 (51%)  
Protocol Pre (DBCG82b) 267 (54%) 296 (58%) 0.3
  Post (DBCG82c) 222 (46%) 215 (42%)  
Tumour size (mm) <21 171 (35%) 190 (37%) 0.1
  21 to 50 259 (53%) 242 (47%)  
  >50 59 (12%) 79 (15%)  
Positive nodes None 29 (6%) 31 (6%) 0.8
  1 to 3 222 (46%) 220 (43%)  
  >3 238 (49%) 260 (51%)  
Histopathology Ductal 428 (88%) 427 (84%) 0.1
  Nonductal 61 (12%) 84 (16%)  
Malignancy grade (ductal only) Grade 1 98 (23%) 97 (23%) 0.7
  Grade 2 213 (50%) 223 (52%)  
  Grade 3 117 (27%) 107 (25%)  
ER Positive 327 (67%) 344 (67%) 0.4
  Negative 160 (33%) 167 (33%)  
  Unknown 2 (0%) 0 (0%)  
PgR Positive 283 (58%) 313 (61%) 0.3
  Negative 205 (42%) 198 (39%)  
  Unknown 1 (0%) 0 (0%)  
HER2 Negative 376 (77%) 404 (79%) 0.6
  Positive 110 (22%) 106 (21%)  
  Unknown 3 (1%) 1 (0%)  
CA IX Negative 386 (79%) 408 (80%) 0.3
  Positive 80 (16%) 71 (14%)  
  Unknown 23 (5%) 32 (6%)  
  1. Shown is the distribution of various clinicopathological parameters, including oestrogen receptor (ER), progesterone receptor (PgR), human epideraml growth factor receptor (HER)2 and carbonic anhydrase (CA) IX among 1,000 high-risk breast cancer patients randomly assigned to receive or not receive postmastectomy radiotherapy.